Brentuximab vedotin

Generic Name
Brentuximab vedotin
Brand Names
Adcetris
Drug Type
Biotech
Chemical Formula
-
CAS Number
914088-09-8
Unique Ingredient Identifier
7XL5ISS668
Background

Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...

Indication

Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...

Associated Conditions
CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
Associated Therapies
-
cancer.gov
·

Nivolumab and AVD the New Standard in Hodgkin Lymphoma

Nivolumab (Opdivo) should be part of initial treatment for advanced Hodgkin lymphoma in teens and adults, according to an NCI-funded trial. Nivolumab combined with AVD chemotherapy showed better progression-free survival and fewer side effects compared to the standard brentuximab-AVD regimen. The trial also reduced the need for radiation therapy, potentially minimizing long-term side effects.
targetedonc.com
·

Incorporating Immunotherapy Into Hodgkin Lymphoma Treatment Strategies

Stephen M. Ansell discusses integrating immunotherapy like nivolumab/AVD into advanced Hodgkin lymphoma treatment, emphasizing personalized care based on patient tolerance, particularly in elderly patients.
© Copyright 2024. All Rights Reserved by MedPath